Randomized, Parallel and Double Blind Placebo-controlled Study for the Evaluation of Both Acute and Chronic Role of Hesperidin Consumption in 100% Orange Juice
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 159
- 试验地点
- 1
- 主要终点
- Systolic Blood Pressure
研究概览
简要总结
The primary aim is to examine both the acute and chronic effects of hesperidin consumption from 100% Florida orange juice in various doses on functional and systemic markers associated with cardiovascular disease (CVD) risks.
详细描述
The aim of this study is to compare the effect of different doses of hesperidin in 100% Florida orange juice (OJ) when regularly or postprandially consumed on cardiovascular risk markers; in addition, the plausible role and mechanism of the hesperidin will be investigated.
The sample size was calculated using a previously available bibliography using systolic blood pressure (SBP) as the primary outcome measure. A total of 84 subjects per study product group were needed, assuming variance components of approximately 20.0, to detect differences between the three groups (control, orange juice and hesperidin-enriched orange juice (10 mm Hg)) with a bilateral significance level of α=0.05 and a power of 80 %.
The sample size was computed to be sufficient to detect differences between treatment groups regarding the evolution in time of SBP levels. Justification of chosen sample size is based on the clinically meaningful difference assigned to δ=10.0 mm Hg, which is equivalent to a difference of approximately 7.4 % in patients with baseline SBP levels of approximately 135 mm Hg. Thus, a sample of 252 participants can be used for the chronic three arm parallel trial design (84 subjects/arm) and will allow us to detect small but clinically relevant differences between the three groups with statistical robustness and direct interpretation in terms of the chronic treatment effect.
To the acute postprandial tests, the investigators have chosen n=20 subjects per arm according to the most studies that have addressed the metabolic effects of a postprandial intervention have been performed using a very similar number of subjects with statistically good quality results.
The statistical analysis will follow the principles specified in the guidelines of the ICHE9 and CPMP/EWP/908/99 ICHE9 Points to Consider on Multiplicity Issues in Clinical Trials.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 65 Years(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Men or women 18-65 years old
- •No evidence of chronic disease
- •No familial CVD history
- •Written informed consent provided before the initial screening visit.
- •Blood pressure (with no drug intervention) >120 mm Hg systolic blood pressure ≤ 159 mmHg
排除标准
- •Body mass index (BMI) ≥ 35 kg/m2
- •Glucose >125 mg/dl
- •Systolic blood pressure ≥ 160 mm Hg and diastolic blood pressure >100 mm Hg or taking antihypertensive medications
- •Total cholesterol >240 mg/dl
- •LDL-cholesterol >160 md/dl
- •TAG >350
- •Pregnant or intending to become pregnant
- •Use of medications, antioxidants, or vitamin supplements
- •Chronic alcoholism
- •Intense physical activity (5h/week)
- •Intestinal disorders
- •Following of a vegetarian diet
- •Anemia (hemoglobin ≤13 g/dL in men and ≤12 g/dL in women)
- •Current or past participation in a clinical trial or consumption of a research product in the 30 days prior to inclusion in the study
- •Failure to follow the study guidelines.
研究组 & 干预措施
Control
Control drink (placebo)
干预措施: Control (Dietary Supplement)
Natural Florida orange juice
100% Florida orange juice (OJ) (natural content of hesperidin)
干预措施: 100% Florida OJ (Dietary Supplement)
Enriched Florida orange juice
100% Florida orange juice (OJ) (enriched hesperidin content)
干预措施: 100% Florida OJ-enriched (Dietary Supplement)
结局指标
主要结局
Systolic Blood Pressure
时间窗: Every 2 weeks for a total of 12 weeks.
During each visit, SBP will be measured after 5 min in a seated position in a comfortable room by the physician. The measurement will be taken in duplicate at 1-min intervals using an automatic sphygmomanometer (OMRON HEM-907; Peroxfarma, Barcelona, Spain), and the average of the two measurements will be calculated.
次要结局
- C-reactive protein (inflammatory marker)(Every 4 weeks for a total of 12 weeks)
- Diastolic Blood Pressure(Every 2 weeks for a total of 12 weeks.)
- Ischemic reactive hyperemia (IRH)(Every 4 weeks for a total of 12 weeks)
- Homocysteine(Every 4 weeks for a total of 12 weeks)
- Platelet aggregation(Every 4 weeks for a total of 12 weeks)
- oxidized LDL (as oxidative stress biomarker)(Every 4 weeks for a total of 12 weeks)
